Cipher Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on developing and marketing innovative treatments, notably Epuris for severe acne. The company boasts strong financial health with a gross margin of 80.4% and an EBITDA margin of 44.9%, indicating efficient operations. However, its return on equity and return on assets are relatively low at 2.9% and 2.6%, suggesting potential concerns regarding profitability and capital efficiency. While the absence of debt is a positive sign, the high margins may not translate into a robust valuation, warranting further investigation into growth prospects.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Gross margin expanded by 7.6 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 11.5pp, demonstrating strong operational leverage.
Both gross margin (+7.6pp) and operating margin (+11.5pp) are expanding simultaneously, indicating the company is scaling profitably.
Exceptional gross margin of 81.4% indicates strong pricing power and competitive moat.
Operating margin of 35.9% demonstrates excellent operational efficiency.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)